We are live on
!
Find out more
FFM
Fairmount Funds Management Portfolio holdings
AUM
$1.38B
1-Year Est. Return
407.79%
This Fund
S&P 500
This Quarter
Est. Return
-0.39%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$581M
AUM Growth
-$48.9M
(-7.8%)
Cap. Flow
+$8.85M
Cap. Flow
% of AUM
1.52%
Top 10 Holdings %
Top 10 Hldgs %
85.53%
Holding
19
New
3
Increased
3
Reduced
–
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$35.9M |
| 2 |
Geron
GERN
|
+$20.2M |
| 3 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$18.3M |
| 4 |
MRUS
Merus
MRUS
|
+$6.52M |
| 5 |
VRNA
Verona Pharma
VRNA
|
+$5.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$33.8M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$29.2M |
| 3 |
Annexon
ANNX
|
+$17.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$12.2B
| $124M | 21.34% |
2,011,647
| – | – |
|
|
NUVL
2
DELISTED
Nuvalent
NUVL
| $75.3M | 12.94% |
2,884,492
+95,511
| +3% | +$2.82M |
|
|
VRNA
3
DELISTED
Verona Pharma
VRNA
| $62.8M | 10.8% |
3,127,429
+251,903
| +9% | +$5.44M |
|
|
ONC
4
BeOne Medicines Ltd
ONC
$32.9B
| $51.6M | 8.88% |
239,443
| – | – |
|
|
5
Enliven Therapeutics
ELVN
$3.63B
| $42.2M | 7.25% |
1,924,938
+1,767,105
| +1,120% | +$35.9M |
|
6
Viridian Therapeutics
VRDN
$1.99B
| $34.8M | 5.99% |
1,369,623
| – | – |
|
7
Cogent Biosciences
COGT
$6.48B
| $29.8M | 5.12% |
2,758,975
| – | – |
|
8
argenx
ARGX
$53.7B
| $27.4M | 4.71% |
73,526
| – | – |
|
|
ATXS
9
DELISTED
Astria Therapeutics
ATXS
| $25.3M | 4.35% |
1,901,397
| – | – |
|
|
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
| $24.2M | 4.15% |
2,040,000
| – | – |
|
11
Tyra Biosciences
TYRA
$1.88B
| $22.8M | 3.92% |
1,416,998
| – | – |
|
|
THRX
12
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $16.6M | 2.85% |
+1,865,671
| New | +$18.3M |
|
|
13
Geron
GERN
$911M
| $15.4M | 2.65% |
+7,104,358
| New | +$20.2M |
|
|
DBVT
14
DBV Technologies
DBVT
$880M
| $11.9M | 2.05% |
706,496
| – | – |
|
15
Trevi Therapeutics
TRVI
$2.46B
| $10.5M | 1.81% |
5,696,515
| – | – |
|
|
MRUS
16
DELISTED
Merus
MRUS
| $6.89M | 1.18% |
+374,435
| New | +$6.52M |
|
|
17
Annexon
ANNX
$965M
| – | – |
-3,358,563
| Closed | -$17.4M |
|
|
18
BioCryst Pharmaceuticals
BCRX
$2.31B
| – | – |
-2,543,107
| Closed | -$29.2M |
|
|
19
Neurocrine Biosciences
NBIX
$17.2B
| – | – |
-283,000
| Closed | -$33.8M |
|
Similar funds
NIP
OCAM
AU
RIM
VC
AO
1CP
OCM
Fairmount Funds Management's Q1 2023 Portfolio in Review
As of Q1 2023, Fairmount Funds Management held 19 positions worth $581M, down 7.8% from $630M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
Fairmount Funds Management's Q1 2023 filing shows 3 new, 3 increased and 3 closed positions. Its largest new stake was Geron: 7,104,358 shares worth $15.4M. The largest sale was Neurocrine Biosciences, an estimated $33.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Fairmount Funds Management's largest Q1 2023 buy was Geron: 7,104,358 shares worth $15.4M.
- Fairmount Funds Management added most to Enliven Therapeutics in Q1 2023, an estimated $35.9M increase.
- Fairmount Funds Management fully exited Neurocrine Biosciences in Q1 2023, selling an estimated $33.8M.
- Fairmount Funds Management's ten largest holdings make up 86% of its $581M portfolio in Q1 2023.
- Fairmount Funds Management opened 3 new positions and closed 3 in Q1 2023.
- Fairmount Funds Management's portfolio value fell 7.8% quarter-over-quarter to $581M.
Based on Fairmount Funds Management's 13F filing for Q1 2023, filed 15 May 2023.